Resveratrol

Generic Name: Resveratrol

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₁₂O_₃

CAS Number: 501-36-0

Unique Ingredient Identifier: Q369O8926L

Background: Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenolic phytoalexin. It is a stilbenoid, a derivate of stilbene, and is produced in plants with the help of the enzyme stilbene synthase. It exists as cis-(Z) and trans-(E) isomers. The trans- form can undergo isomerisation to the cis- form when heated or exposed to ultraviolet irradiation. In a 2004 issue of Science, Dr. Sinclair of Harvard University said resveratrol is not an easy molecule to protect from oxidation. It has been claimed that it is readily degraded by exposure to light, heat, and oxygen. However, studies find that Trans-resveratrol undergoes negligible oxidation in normal atmosphere at room temperature.

Indication: Being investigated for the treatment of Herpes labialis infections (cold sores).

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Regulation of Intestinal and Hepatic Lipoprotein Secretion by Resveratrol

Phase 2

Completed

Conditions: Dyslipidaemia
Insulin Resistance

Interventions: Drug: Resveratrol

First Posted Date: 2011-10-14

Last Posted Date: 2014-05-06

Lead Sponsor: University Health Network, Toronto

Target Recruit Count: 8

Registration Number: NCT01451918

Locations: 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada

Resveratrol in Postmenopausal Women With High Body Mass Index

Phase 1

Completed

Conditions: Healthy, no Evidence of Disease

Interventions: Drug: resveratrol
Other: laboratory biomarker analysis

First Posted Date: 2011-06-10

Last Posted Date: 2014-10-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT01370889

Locations: 🇺🇸
Arizona Cancer Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Health Sciences Center, Tucson, Arizona, United States

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus
Insulin Resistance

Interventions: Drug: Resveratrol

First Posted Date: 2011-05-17

Last Posted Date: 2022-03-08

Lead Sponsor: Albert Einstein College of Medicine

Target Recruit Count: 20

Registration Number: NCT01354977

Locations: 🇺🇸
Albert Einstein College of Medicine, Bronx, New York, United States

A Study of Resveratrol as Treatment for Friedreich Ataxia

Phase 1

Completed

Conditions: Friedreich Ataxia

Interventions: Drug: Resveratrol

First Posted Date: 2011-04-21

Last Posted Date: 2014-01-22

Lead Sponsor: Murdoch Childrens Research Institute

Target Recruit Count: 27

Registration Number: NCT01339884

Locations: 🇦🇺
Monash Medical Centre, Southern Health, Clayton, Melbourne, Victoria, Australia

Use of Resveratrol to Decrease Acute Secondary Brain Injury Following Sports-Related Concussions in Boxers

Phase 1

Completed

Conditions: Sports Concussion

Interventions: Drug: Placebo
Drug: Resveratrol

First Posted Date: 2011-03-23

Last Posted Date: 2021-02-11

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 12

Registration Number: NCT01321151

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

Resveratrol in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy, no Evidence of Disease

Interventions: Drug: resveratrol
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2008-07-25

Last Posted Date: 2014-10-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT00721877

Locations: 🇺🇸
Arizona Cancer Center - Tucson, Tucson, Arizona, United States

Mechanisms of Metabolic Regulation of Resveratrol on Humans With Metabolic Syndrome

Phase 2

Withdrawn

Conditions: Insulin Resistance

Interventions: Drug: Placebo
Drug: Resveratrol

First Posted Date: 2008-04-09

Last Posted Date: 2015-03-04

Lead Sponsor: University of California, San Francisco

Registration Number: NCT00654667

Locations: 🇺🇸
University of California, San Francisco, California, United States

Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery

Phase 1

Completed

Conditions: Adenocarcinoma of the Rectum
Stage I Colon Cancer
Stage I Rectal Cancer
Stage II Colon Cancer
Stage II Rectal Cancer
Stage III Colon Cancer
Adenocarcinoma of the Colon
Stage III Rectal Cancer

Interventions: Drug: resveratrol
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2007-02-12

Last Posted Date: 2014-09-15

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT00433576

Locations: 🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

Resveratrol for Patients With Colon Cancer

Phase 1

Completed

Conditions: Colon Cancer
Cancer

Interventions: Drug: Resveratrol

First Posted Date: 2005-11-21

Last Posted Date: 2014-06-20

Lead Sponsor: University of California, Irvine

Target Recruit Count: 11

Registration Number: NCT00256334

Locations: 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-12-09

Last Posted Date: 2012-12-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT00098969

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
🇬🇧
Leicester Royal Infirmary, Leicester, England, United Kingdom

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy